Thor Energy CEO Andrew Hume caught up with DirectorsTalk to discuss the company’s strategic pivot to natural hydrogen and helium. Hume detailed three recent asset deals, including divestments to Metals One, DISA, and TIVAN, which will generate funding of around $6 million...
Real Estate Credit Investments published its monthly fact sheet for 30 September 2025, showing a diversified portfolio of 23 investments valued at £279.5 million and cash of £41.4 million...
Telcos are turning back-office infrastructure into strategic growth engines by reimagining OSS/BSS as platforms for real-time insight, automation, and personalisation...
Flooring is a strategic choice that affects property value, safety and sustainability. Selecting the right material means balancing cost, performance and compliance to support both immediate function and long-term returns...
Ilika CEO Graeme Purdy spoke with DirectorsTalk to mark the company’s completion of its Goliath pilot line, now fully operational with the final commissioning of its pouch cell assembly process...
Touchstone Exploration has launched a retail offer to raise up to £0.68 million through the issue of up to 6.18 million new shares at 11 pence each via the BookBuild platform...
ICG Enterprise Trust has completed the realisation of its investment in Froneri, generating cash proceeds of €41 million. Froneri, a leading ice cream manufacturer and distributor, was ICGT’s largest portfolio holding at 2.7% of total assets as of 31 July 2025...
VinaCapital Vietnam Opportunity Fund recorded a -2.2% NAV total return in USD terms for the year ended 30 June 2025, with NAV per share down 4% to USD7.13 and share price down 7.8% to USD5.77...
Pantheon International reported an unaudited NAV per share of 510.7p as at 30 September 2025, unchanged from the prior month. The Company generated £27.6 million in net portfolio cash flow, with £39.7 million of distributions exceeding £12.1 million of capital calls...
GSK has received FDA approval for Blenrep (belantamab mafodotin-blmf) with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least two prior therapies...
Thor Energy CEO Andrew Hume caught up with DirectorsTalk to discuss the company’s strategic pivot to natural hydrogen and helium. Hume detailed three recent asset deals, including divestments to Metals One, DISA, and TIVAN, which will generate funding of around $6 million...
Real Estate Credit Investments published its monthly fact sheet for 30 September 2025, showing a diversified portfolio of 23 investments valued at £279.5 million and cash of £41.4 million...
Telcos are turning back-office infrastructure into strategic growth engines by reimagining OSS/BSS as platforms for real-time insight, automation, and personalisation...
Flooring is a strategic choice that affects property value, safety and sustainability. Selecting the right material means balancing cost, performance and compliance to support both immediate function and long-term returns...
Ilika CEO Graeme Purdy spoke with DirectorsTalk to mark the company’s completion of its Goliath pilot line, now fully operational with the final commissioning of its pouch cell assembly process...
Touchstone Exploration has launched a retail offer to raise up to £0.68 million through the issue of up to 6.18 million new shares at 11 pence each via the BookBuild platform...
ICG Enterprise Trust has completed the realisation of its investment in Froneri, generating cash proceeds of €41 million. Froneri, a leading ice cream manufacturer and distributor, was ICGT’s largest portfolio holding at 2.7% of total assets as of 31 July 2025...
VinaCapital Vietnam Opportunity Fund recorded a -2.2% NAV total return in USD terms for the year ended 30 June 2025, with NAV per share down 4% to USD7.13 and share price down 7.8% to USD5.77...
Pantheon International reported an unaudited NAV per share of 510.7p as at 30 September 2025, unchanged from the prior month. The Company generated £27.6 million in net portfolio cash flow, with £39.7 million of distributions exceeding £12.1 million of capital calls...
GSK has received FDA approval for Blenrep (belantamab mafodotin-blmf) with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least two prior therapies...
